Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $90.3 million.

  • BeOne Medicines' Change in Accured Expenses rose 888.73% to $90.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.6 million, marking a year-over-year increase of 2054.7%. This contributed to the annual value of $111.4 million for FY2024, which is 3817.48% down from last year.
  • As of Q3 2025, BeOne Medicines' Change in Accured Expenses stood at $90.3 million, which was up 888.73% from $128.0 million recorded in Q2 2025.
  • BeOne Medicines' 5-year Change in Accured Expenses high stood at $234.3 million for Q4 2021, and its period low was -$79.3 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was $44.0 million (2022), whereas its average is $38.9 million.
  • Per our database at Business Quant, BeOne Medicines' Change in Accured Expenses crashed by 239872.12% in 2022 and then surged by 39770.21% in 2023.
  • Quarter analysis of 5 years shows BeOne Medicines' Change in Accured Expenses stood at $234.3 million in 2021, then crashed by 81.22% to $44.0 million in 2022, then soared by 195.51% to $130.0 million in 2023, then tumbled by 56.38% to $56.7 million in 2024, then skyrocketed by 59.15% to $90.3 million in 2025.
  • Its last three reported values are $90.3 million in Q3 2025, $128.0 million for Q2 2025, and -$52.4 million during Q1 2025.